Efficacy and Safety Study of a Combination Product [Drug:BCI-024 (Buspirone) and Drug:BCI-049 (Melatonin)] to Treat Major Depressive Disorder (MDD)
Completed · Phase 2 · Has a placebo group
Conditions studied: Major Depressive Disorder
In brief
The primary objective of this study are to evaluate the synergistic effect of a combination product, consisting of drug BCI-024 (buspirone) and drug BCI-049 (melatonin), in reducing symptoms of depression in patients with Major Depressive Disorder. The safety and tolerability of the combination product will also be evaluated as measured by adverse events and vital signs.
Key facts
- Study ID
- NCT00705003
- Run by
- Massachusetts General Hospital
- People needed
- 142
- Starts
- 2008-05-01
- Expected to finish
- 2008-12-01
- Last updated by the study team
- 2014-06-18
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Subjects will be male and female subjects between the ages of 18 to 65 meeting the Diagnostic and Statistical Manual of Mental Disorders-IV-Text Revision (DSM-IV-TR) criteria for Major Depressive Disorder with a Quick Inventory of Depressive Symptomatology-16 Item Self Report (QIDS-SR16) score of >14 at the Screening and Baseline Visits.
- Female subjects must be on a stable and medically reliable form of birth control, must agree to continue use of this birth control during the study, and must have negative urine pregnancy tests at the Screening Visit.
You may not qualify if…
- Subjects with any other psychiatric Axis-I disorder as a principal diagnosis within 6 months of screening or subjects with a history of obsessive compulsive disorder, psychotic disorder, bipolar disorder, or mental retardation at any time are not eligible for the study.
- Subjects who pose a suicidal risk or who have a history of eating disorder or substance dependence within 6 months of screening, or a history of substance abuse within 3 months of screening are also ineligible.
- Subjects with clinically significant abnormalities on any Screening or Baseline assessments, including laboratory tests, are excluded.
- Subjects with a known intolerance to either buspirone or melatonin are excluded, as are subjects with clinically significant medical or psychiatric conditions that might be detrimental to the subject should they participate in the study.
- Subjects who have used selective serotonin reuptake inhibitors (SSRIs) within 2 weeks of Screening (within 4 weeks for fluoxetine) are excluded as are subjects requiring concomitant use of antipsychotic and anxiolytic medications and any drugs with known psychotropic properties. Concomitant medications that are not excluded by the protocol and that are taken chronically must be at a stable dosage for at least 4 weeks prior to screening.
Where it is running
- Collaborative Neuroscience Network, Inc. — Garden Grove, California, United States
- Synergy Research Centers — San Diego, California, United States
- Atlanta Institute of Medicine & Research, Inc. — Altanta, Georgia, United States
- Capital Clinical Research Associates — Rockville, Maryland, United States
- NorthCoast Clinical Trials — Beachwood, Ohio, United States
- CRI Worldwide — Philadelphia, Pennsylvania, United States
- FutureSearch Clinical Trials, L.P. — Austin, Texas, United States
- FutureSearch Trials of Dallas, L.P. — Dallas, Texas, United States
- Claghorn-Lesem Research Clinic, Ltd. — Houston, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.